Phase 3 FIRST Trial in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Subgroup Analysis of Patients From Canada and the United States

Abstract

In the FIRST trial, lenalidomide (LEN) + low-dose dexamethasone until disease progression (Rd cont) showed significant PFS and OS benefits compared with melphalan, prednisone, and thalidomide (MPT) in transplant-ineligible (TNE) pts with NDMM. PFS was also extended with Rd cont vs Rd for 18 cycles (Rd18). These results support the use of frontline alkylator-free continuous oral therapy for TNE pts with NDMM and established Rd cont as a standard of care, as reflected by clinical guidelines in Canada, the US, and Europe.